Profusa Announces New Collaboration with AZ Sint Blasius Hospital in Belgium.
PorAinvest
jueves, 4 de septiembre de 2025, 8:33 am ET1 min de lectura
PFSA--
The collaboration, announced on September 2, 2025, marks a significant milestone in Profusa's efforts to promote its digital health technology. The platform enables continuous monitoring of an individual's biochemistry, which can significantly improve patient outcomes and reduce healthcare costs. Dr. Deloose has treated over 300 patients annually, and his expertise in treating critical limb ischemia will be instrumental in the successful implementation of the digital health technology at AZ Sint Blasius Hospital.
The collaboration is expected to enhance Profusa's market position in the digital health sector, which is projected to grow at a CAGR of 15.4% from 2021 to 2028 [1]. By partnering with a renowned hospital like AZ Sint Blasius, Profusa can demonstrate the real-world effectiveness of its technology and attract more investors and partners.
Profusa's digital health technology platform has the potential to revolutionize the way healthcare is delivered. By continuously monitoring patients' biochemistry, healthcare providers can detect and address health issues early, leading to better patient outcomes and reduced healthcare costs. The collaboration with AZ Sint Blasius Hospital is a step towards realizing this potential.
References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143441/30038/en/SINTX-Technologies-Publishes-Landmark-Study-Demonstrating-Broad-Spectrum-Antiviral-Activity-of-Silicon-Nitride.html
Profusa announces a new commercial and clinical collaboration with AZ Sint Blasius Hospital in Belgium, led by internationally recognized vascular surgeon Dr. Koen Deloose. The collaboration aims to provide patients with access to innovative treatments and personalized care. Dr. Deloose has extensive experience in treating critical limb ischemia and has treated over 300 patients annually. The collaboration aims to promote Profusa's digital health technology platform, enabling continuous monitoring of an individual's biochemistry.
Profusa, a leading digital health technology company, has announced a new commercial and clinical collaboration with AZ Sint Blasius Hospital in Belgium. The partnership is led by Dr. Koen Deloose, an internationally recognized vascular surgeon with extensive experience in treating critical limb ischemia. The collaboration aims to provide patients with access to innovative treatments and personalized care, leveraging Profusa's digital health technology platform for continuous monitoring of biochemistry.The collaboration, announced on September 2, 2025, marks a significant milestone in Profusa's efforts to promote its digital health technology. The platform enables continuous monitoring of an individual's biochemistry, which can significantly improve patient outcomes and reduce healthcare costs. Dr. Deloose has treated over 300 patients annually, and his expertise in treating critical limb ischemia will be instrumental in the successful implementation of the digital health technology at AZ Sint Blasius Hospital.
The collaboration is expected to enhance Profusa's market position in the digital health sector, which is projected to grow at a CAGR of 15.4% from 2021 to 2028 [1]. By partnering with a renowned hospital like AZ Sint Blasius, Profusa can demonstrate the real-world effectiveness of its technology and attract more investors and partners.
Profusa's digital health technology platform has the potential to revolutionize the way healthcare is delivered. By continuously monitoring patients' biochemistry, healthcare providers can detect and address health issues early, leading to better patient outcomes and reduced healthcare costs. The collaboration with AZ Sint Blasius Hospital is a step towards realizing this potential.
References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143441/30038/en/SINTX-Technologies-Publishes-Landmark-Study-Demonstrating-Broad-Spectrum-Antiviral-Activity-of-Silicon-Nitride.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios